Has Ajit Raisinghani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $60,479 in general payments to Ajit Raisinghani, MD across 98 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ajit Raisinghani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ajit Raisinghani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ajit Raisinghani, MD

Cardiovascular Disease · San Diego, CANPI 1831292796

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,321 of the $60,479 with a category attached, or 81.5%. 8 manufacturers reported payments, led by Kiniksa Pharmaceuticals, Ltd. at 52.8% of the total. Reporting peaked in 2024 at $28,195 and has fallen 99.7% since, to $72 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,479in general payments, 2019–2025

Across 98 payments — averaging $617.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kiniksa Pharmaceuticals, Ltd.$32K
Kiniksa Pharmaceuticals International, PLC$27K
Abbott$2K
Boston Scientific$224
Edwards Lifesciences$72
Lantheus Medical Imaging, Inc.$34
plus $37 from 2 others

$634,766in research payments, 2019–2025

Across 113 payments — averaging $5617.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Lantheus Medical Imaging, Inc.$368K
CSL Behring$154K
AstraZeneca$56K
Janssen Research & Development, LLC$54K
GSK$3K
Merck$364

What the payments were for

Speaking & faculty fees$49,32182%
Travel & lodging$8,56414%
Food & beverage$2,5954%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kiniksa Pharmaceuticals, Ltd.	38	$31,941
Kiniksa Pharmaceuticals International, PLC	40	$26,560
Abbott	12	$1,611
Boston Scientific	2	$224
Edwards Lifesciences	2	$72
Lantheus Medical Imaging, Inc.	2	$34
E.r. Squibb & Sons, L.L.C.	1	$19
Philips North America LLC	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ARCALYST$45,270
MitraClip System$126

How this compares

$60,479 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$197,709

Medicare patients

1,406

Services billed

2,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	341	$437,374
EntrestoSacubitril/Valsartan	141	$195,642
JardianceEmpagliflozin	90	$111,387
Repatha SureclickEvolocumab	74	$58,859
XareltoRivaroxaban	32	$45,508
FarxigaDapagliflozin Propanediol	35	$38,407
Repatha SyringeEvolocumab	23	$27,616
Praluent PenAlirocumab	32	$16,376
Rosuvastatin Calcium	542	$10,218
Ezetimibe	170	$5,761
Metoprolol Succinate	315	$5,073
Atorvastatin Calcium	402	$4,779
Losartan Potassium	225	$3,268
Flecainide Acetate	59	$3,141
Valsartan	58	$2,893

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in San Diego

Lori DanielsSan Diego$278K
Michael WilkinsonSan Diego$145K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M
Pam Taubla Jolla$1.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →